Podcast Pearls: Essential Biomarker Testing in GI Cancers

In this downloadable PDF transcript from a CCO podcast, read an expert discussion of current actionable biomarker testing considerations for gastrointestinal cancers.
John L. Marshall, MD
Format: Adobe Acrobat (.pdf)
File Size: 596 KB
Released: August 18, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Merck Sharp & Dohme Corp.

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Released: October 5, 2021

EPOCH final analysis of TARE with yttrium-90 + chemotherapy for unresectable colorectal liver metastases from ESMO 2021 reported by Clinical Care Options (CCO)

Released: October 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue